NeuroVision is a groundbreaking brand that specializes in the development of retinal and fluid biomarkers to assess neurodegenerative conditions. They offer a range of innovative products and services aimed at providing clinicians with valuable insights and patients with motivation for lifestyle risk reduction. One of NeuroVision's key offerings is their proprietary blood tests, which enable individuals to monitor the levels of essential neurological biomarkers.

This not only provides feedback to healthcare professionals but also encourages patients to actively pursue lifestyle changes that can potentially delay cognitive decline. In addition, NeuroVision has developed the Afina® system, a state-of-the-art imaging technology that visualizes and measures retinal autofluorescence. By capturing and analyzing the fluorescence emitted by protein deposits in the retina, doctors can better assess various conditions that manifest in the retina.

Published research supports the correlation between amyloid beta deposits in the retina and those found in the brain, a hallmark sign of Alzheimer's disease. Furthermore, NeuroVision is actively involved in the development of software for retinal image analysis. This software enables the import, processing, and display of retinal images, improving the identification and management of retinal diseases.

NeuroVision collaborates closely with pharmaceutical companies to explore potential complementary and companion biomarker opportunities. Their commitment to scientific research and strategic partnerships ensures they remain at the forefront of neurodegenerative condition assessment. Please note, all NeuroVision products are currently investigational and are limited by federal law to investigational use